Saturday 17 October 2026
Export RAPP’s income statement to Excel — free account
Rapport Therapeutics, Inc.
RAPP Healthcare Biotechnology
In the quarter to June 2026, EPS fell 58.7% and free cash flow fell 64.8%, each against the same quarter a year earlier.
27.57
2.00
−6.76%
Follow RAPP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(23.41%) | (28.22%) | (28.33%) | (39.96%) | |
| (22.55%) | (26.95%) | (26.83%) | (36.85%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(19.18%) | (23.11%) | (22.86%) | (32.60%) | |
Average Days of Receivables |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.05) | (2.26) | (1.71) | (2.04) | |
Free Cash Flow |
(77.89) | (88.09) | (80.71) | (96.96) | |
Capital Expenditures |
(0.67) | (0.62) | (0.41) | (0.27) | |
| Other line items | |||||
Cash ROIC |
(7.60%) | (9.03%) | (8.51%) | (11.29%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.79 | 0.78 | 0.75 | 0.70 | |
Depreciation/Fixed assets |
0.40 | (0.13) | (0.13) | 0.03 | |
Capex/Depreciation |
(0.54) | 1.63 | 1.27 | (3.75) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.04) | (2.25) | (1.70) | (2.04) | |
Capex per Share |
(0.02) | (0.02) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates